DHR vs JNJ
DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | DHR | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $215.11 | $273.04 | |
| Market cap as of 2026-08-24 | $151.2B | $658.0B | |
| P/E as of 2026-08-24 | 38.19 | 31.66 | JNJ lower |
| PEG as of 2026-08-24 | 3.74 | 3.39 | JNJ lower |
| Net margin as of 2026-08-24 | +15.9% | +21.5% | JNJ higher |
| Gross margin as of 2026-08-24 | +58.6% | +68.0% | JNJ higher |
| Operating margin as of 2026-08-24 | +20.4% | +25.7% | JNJ higher |
| ROE as of 2026-08-24 | +7.7% | +25.7% | JNJ higher |
| ROA as of 2026-08-24 | +4.7% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-24 | 0.51 | 0.58 | DHR lower |
| Revenue growth (YoY) as of 2026-08-24 | +4.6% | +8.1% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | +6.2% | JNJ higher |
| Dividend yield as of 2026-08-24 | +0.5% | +3.1% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 0.77 | -0.02 | |
| 1-year return as of 2026-08-24 close | +1.6% | +52.3% | JNJ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.